The rise of carbapenem resistance in Europe: just the tip of the iceberg?

Antimicrobial Resistance and Infection Control

Anna-Pelagia Magiorakos²  Carl Suetens²  Dominique L Monnet²  Carlo Gagliotti¹  Ole E Heuer² 

[1] Agenzia Sanitaria e Sociale Regionale Emilia-Romagna, Bologna, Italy

[2] European Centre for Disease Prevention and Control, Tomtebodavägen 11A, Stockholm SE-171 83, Sweden

关键词: β-lactamases;    Europe;    Klebsiella infections;    Gram-negative bacteria;    Antimicrobial drug resistance;    Carbapenems;   

Others  :  790942
DOI  :  10.1186/2047-2994-2-6

 received in 2012-06-26, accepted in 2013-01-29,  发布年份 2013

【 摘 要 】

The European Antimicrobial Resistance Surveillance Network (EARS-Net) collects data on carbapenem resistance from invasive bacterial infections. Increasing percentages of carbapenem resistance in K. pneumoniae isolates were reported from progressively more countries in Europe between 2005 and 2010. A trend analysis showed increasing trends for Greece, Cyprus, Hungary and Italy (p < 0.01). EARS-Net collects data on invasive bacterial isolates, which likely correspond to a fraction of the total number of infections. Increasing reports of community cases suggest that dissemination of carbapenem-resistant K. pneumoniae has penetrated into the community. Good surveillance and infection control measures are urgently needed to contain this spread.

【 授权许可】

   
2013 Magiorakos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]European Centre for Disease Prevention and Control: Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. Stockholm: ECDC; 2011.
• [2]Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al.: Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010, 15(46):pii:19711.
• [3]Glupczynski Y, Huang TD, Bouchahrouf W, Rezende de Castro R, Bauraing C, Gerard M, et al.: Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. Int J Antimicrob Agents 2012, 39:168-72.
• [4]Poirel L, Barbosa-Vasconcelos A, Simões RR, Martins Da Costa P, Liu W, Nordmann P: Environmental KPC-producing Escherichia coli, Portugal. Antimicrob Agents Chemother 2012, 56:1662-3.
• [5]Potron A, Poirel L, Bussy F, Nordmann P: Occurrence of the carbapenem-hydrolyzing beta-lactamase gene blaOXA-48 in the environment in Morocco. Antimicrob Agents Chemother 2011, 55:5413-4.
• [6]European Centre for Disease Prevention and Control: Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2011.
• [7]Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
• [8]Bush K, Jacoby GA: Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010, 54:969-76.
• [9]Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP: Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-106.
• [10]Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al.: Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-6.
• [11]Centers for Disease Control and Prevention: Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009, 58:256-60.
• [12]Akova M, Daikos GL, Tzouvelekis L, Carmeli Y: Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clinical Microbiol Infect. 2012, 18:439-48.
• [13]Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, et al.: Controlling the spread of carbapenemase-producing Gram-negatives: Therapeutic approach and infection control. Clin Microbiol Infect 2010, 102-11.